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Background: Prostate stem cell antigen (PSCA) is upregulated in prostate cancer tissues. Here we aimed to study
the therapeutic efficacy of a monoclonal antibody of PSCA-labeled I131 (I131-PSCA-mAb) in orthotopic mouse models
of prostate cancer.
Methods: The proliferation, apoptosis and invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb were
measured by methyl thiazolyl tetrazolium assay, flow cytometry and transwell culture, respectively. The human prostate
cancer models were established by orthotopic implantation of PC-3 and LNCaP cells in nude mice. I131-PSCA-mAb
distribution and tumor cell apoptosis in the tumor-bearing nude mice were measured.
Results: The inhibitory and apoptosis rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb reached a maximum of
84%, 80% and 50%, 46%, respectively, which were obviously higher than in the cells treated with I131-IgG or PSCA-mAb.
The invaded number of PC-3 and LNCaP cells treated with I131-PSCA-mAbe was significantly reduced (P < 0.01) compared
with the control group. The ratios of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in tumor-bearing
nude mice were increased with time and reached the highest level after 8 h. T/NT stayed above 3.0 after 12 h, and the
tumor could still be developed after 24 h. The number of apoptotic cells in tumor tissue of nude mice treated with
I131-PSCA-mAb was larger than that in the control group.
Conclusion: I131-PSCA-mAb has the potential to become a new targeted therapy drug for the treatment of prostate
cancer.
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Prostate cancer is one of the most frequently diagnosed
malignancies worldwide and has become one of the
leading causes of cancer-related death in men, only
behind lung cancer [1,2]. Some patients with metastatic
disease die within 2–3 years of diagnosis, whereas others
with organ-confined disease can live for 10–20 years,
which indicates that prostate tumors might have tremen-
dous genomic diversity [3].
Androgens could contribute to the initial growth of
prostate cancer [4]. In 1941, Huggins and Hodges suc-
cessfully applied androgen deprivation therapy (ADT) by
the injection of estrogens in metastatic prostate cancer* Correspondence: yangdiandongydd@hotmail.com; gaozhenligg@hotmail.com
Department of Urology, Yantai Yuhuangding Hospital Affiliated to Medical
College of Qingdao University, NO.20 East Yuhuangding Road, 264000 Yantai,
China
© 2013 Yu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.patients in the form of surgical castration [5,6]. Within
1–2 years after initial response, progression of prostate
cancer typically occurs; ADT could be considered as the
treatment of choice for patients with advanced meta-
static prostate cancer [7,8]. However, most prostate tu-
mors ultimately progress to hormone-resistant prostate
cancer (HRPC), which is androgen-independent growth,
and resistance inevitably occurs within a few years, while
antiandrogen therapy is initially effective [9]. Though
early detection and treatment have improved signifi-
cantly, biochemical recurrence might happen to almost
40% of men after radical retropubic prostatectomy [10].
The clinical manifestations of HRPC include increased
concentrations of prostate serum antigen (PSA), bone
metastases, soft-tissue/lymph node metastases and sub-
stantive pain [11].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Yu et al. European Journal of Medical Research 2013, 18:56 Page 2 of 7
http://www.eurjmedres.com/content/18/1/56Prostate stem cell antigen (PSCA) belongs to the Thy-1/
Ly-6 family of the glycosylphosphatidylinositol-anchored
cell membrane glycoprotein, which can overexpress in
prostate cancer tissues [12]. Although PSCA expression
has been detected in all stages of prostate cancer, the in-
creased expression level of PSCA is positively correlated
with biochemical recurrence, advanced stage, transition to
the castration-resistant state and metastatic progression
[13-16]. Ahmad et al. reported that a plasmid-based vac-
cine against PSCA may have the potential to be used in
multimodal treatment programs for prostate cancer [17].
Saffran et al. found that administration of anti-PSCA
mAbs could inhibit metastasis to distant sites and restrain
the growth of established orthotopic tumor, which could
significantly prolong the survival time of tumor-bearing
mice [18]. However, the therapeutic outcomes using anti-
PSCA mAbs for prostate cancer patients are very poor
and limited. There are few studies on radioimmunother-
apy guided by anti-PSCA mAbs for prostate cancer. The
interesting area indicating the region of interest has been
used in many surveillance systems, such as medical image
processing [19].
In this study, anti-PSCA mAbs labeled with I131 (I131-
PSCA-mAb) were made to investigate the potential thera-
peutic efficacy of I131-PSCA-mAb for prostate cancer. The
proliferation abilities, apoptosis and invasion abilities of
PC-3 and LNCaP cells treated with I131-PSCA-mAb
in vitro were measured by methyl thiazolyl tetrazolium
(MTT) assay, flow cytometry and transwell culture, respect-
ively. Furthermore, human prostate cancer xenograft nude
mice models were established by injection of androgen-
dependent LNCaP cells and androgen-independent PC-
3 cells. The distribution and variation of I131-PSCA-mAb
in the tumor-bearing nude mice over time were measured
by single-photon emission computerized tomography
(SPECT) and the ROI method. Tumor cell apoptosis was
detected by the terminal-deoxynucleotidyl transferase-
mediated nick end labeling (TUNEL) technique.
Methods
Cell culture
Human prostate cancer PC-3 cell and LNCaP cell strains
were purchased from Nanjing Keygen Biotechnology
Co., Ltd. The PC-3 cells and LNCaP cells were main-
tained in RPMI-1640 and DMEM/F12 (GIBCO, USA)
supplemented with 10% fetal calf serum (GIBCO, USA),
respectively. All cells were incubated in a humidified air
incubator with 5% CO2 at 37°C. The PC-3 cells and
LNCaP cells at exponential growth phase were digested
with 0.25% trypsin for inoculation.
Animals
All animal studies were approved by the China Ethics
Committee and performed in accordance with theethical standards. A total of 15 12-week-old male nude
mice (BALB/c-nu/nu) were recruited for the study. The
male nude mice were from the Model Animal Research
Center of Nangjing University. The nude mice were
raised under the sterile barrier system with constant
temperature (25-27°C) and humidity (40-50%) as well as ex-
perimental conditions accorded with the specific pathogen-
free (SPF) standard. The nude mice were freely fed with
high-pressure-sterilized forage and water.
Establishment of prostate cancer models
The models of human prostate cancer were established
in nude mice by orthotopic implantation. The PC-3 cells
or LNCaP cells were inoculated into the anterior pros-
tate of each nude mouse at the density of 2 × 107 cells/ml.
The 15 male nude mice were randomly divided into three
groups: the group inoculated with 100 μl LNCaP cells
(n = 5), the group inoculated with 100 μl PC-3 cells (n = 5)
and the control group inoculated with 100 μl normal sa-
line (n = 5).
Labeling and identification of I131
The mouse anti-human PSCA IgG monoclonal anti-
bodies (PSCA-mAb), which were specific to human
orthotopic tumors in the mice and did not affect en-
dogenous PSCA expression in these animals, were pur-
chased from Sigma Co. in the USA. The labeling and
identification of I131 in PSCA-mAb and control IgG
were conducted at Shandong University.
Measurements of cell inhibitory rate, apoptosis and
invasion
The PC-3 and LNCaP cells were divided into four
groups treated with normal saline, I131-PSCA-mAb, I131-
IgG or PSCA-mAb, respectively. The difference in prolif-
eration ability of PC-3 and LNCaP cells treated with the
above three drugs including I131-PSCA-mAb, I131-IgG
and PSCA-mAb (2 ug/ul) in vitro was measured by
MTT assay. Briefly, 100 μl cells with the density of 2 ×
104 cells/ml was seeded into each well of a 96-well plate
and incubated for 48 h. MTT (50 μl, 1 mg/ml) was
added to each well, and the cells were incubated for 4 h.
DMSO (150 μl) was later added to each well to solubilize
the formazan crystals. The absorbance was read at
570 nm using a microplate reader. All determinations
were carried out in triplicate. The inhibitory rate (IR) of
the cell proliferation was calculated according to the
equation: IR (%) = (1-A/A’) × 100% where A refers to the
absorbance of the drug-treated group and A’ refers to
the absorbance of the control group.
The difference in apoptosis of PC-3 and LNCaP cells
treated with drugs in vitro was measured by an apoptosis
assay kit according to the manufacturer’s instructions.
AnnexinV-FITC (5 ul) was added to the cell suspension,
Figure 1 The inhibitory rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb, I131-IgG or PSCA-mAb (*P < 0.05, compared with the
LNCaP cells treated with I131-PSCA-mAb; #P < 0.05, compared with the PC-3 cells treated with I131-PSCA-mAb).
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ing. The cells were incubated for 5–15 min at room
temperature out of direct sunlight. Cell apoptosis was
detected using flow cytometry (GUAVA, Millipore)
within 1 h.
Cell invasion ability was determined using a transwell
chamber (Corning, Mexico) with a pore size of 8.0 μm.
Cells with the density of 1 × 105 cells/ml in serum-free
medium were added to each insert. After being cultured
for 10 h at 37°C, the cells that had invaded the mem-
brane were fixed by 4% paraformaldehyde and stained
with 0.1% crystal violet. Five fields were selected ran-
domly from the central and surrounding membrane, and
then cells in every field were counted. All determina-
tions were carried out in triplicate.
SPECT for tumor-bearing nude mice
SPECT was performed on five tumor-bearing nude mice
inoculated with androgen-independent PC-3 cells and five
tumor-bearing nude mice inoculated with androgen-
dependent LNCaP cells at 1 h, 4 h, 8 h, 12 h and 24 h afterFigure 2 The apoptosis of PC-3 and LNCaP cells treated with drugs. (a
PSCA-mAb; c: LNCaP cells treated with I131-IgG; d: LNCaP cells treated with
treated with PSCA-mAb; g: PC-3 cells treated with I131-IgG; h: PC-3 cells treintravenous injection of 200 ul I131-PSCA-mAb (1 ug/ul)
using a pinhole collimator. In order to block the uptake of
I131 by the thyroid gland, nude mice were treated with a
saturated solution of potassium iodide before the intraven-
ous injection. The matrix was 128 × 128, and the zoom
value was 1.33. The image data per frame were 2 × 105
pixels. The ratio of I131-PSCA-mAb in tumor to intramus-
cular I131-PSCA-mAb (T/NT) in the tumor-bearing nude
mice with time was measured using the ROI method with
GE Xeleris software.Detection of tumor cell apoptosis
Apoptotic cells were detected by the TUNEL technique
with an in situ cell death detection kit (Beyotime, China).
The paraffin-embedded prostate tissues of the control
group and experimental group were cut into 3-μm-thick
sections and underwent routine deparaffinization and rehy-
dration. Sections were incubated with the TUNEL reaction
mixture containing terminal-deoxynucleotidyl transferase
and label solution at 37°C for 1 h. Converted peroxidase: LNCaP cells treated with normal saline; b: LNCaP cells treated with
I131-PSCA-mAb; e: PC-3 cells treated with normal saline; f: PC-3 cells
ated with I131-PSCA-mAb).
Figure 3 The invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb, I131-IgG or PSCA-mAb (**P < 0.01, compared with
the cells treated with normal saline).
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used as a chromogen for final visualization.
Statistical analysis
The measurement data were expressed as mean ± stand-
ard deviation and analyzed by t-test using SPSS version
17.0 software (Chicago, IL, USA). Differences were sig-
nificantly statistical at P <0.05.
Results
Cell inhibitory rate
The inhibitory rates of PC-3 and LNCaP cells treated
with drugs were measured by MTT assay (Figure 1).
Compared with the control group, the proliferations of
PC-3 and LNCaP cells treated with I131-PSCA-mAb,
PSCA-mAb or I131-IgG were inhibited to differentFigure 4 The SPECT for tumor-bearing nude mice at 1 h, 4 h, 8 h, 12
(a: tumor-bearing nude mice inoculated with androgen-independent PC-3
dependent LNCaP cells).degrees. The inhibitory rates of PC-3 and LNCaP cells
reached the maximum of 84% and 80%, respectively,
when cells were treated with I131-PSCA-mAb. The in-
hibitory rates of PC-3 and LNCaP cells treated with I131-
PSCA-mAb were significantly higher than those of the
cells treated with PSCA-mAb or I131-IgG (P < 0.05).
Cell apoptosis
The apoptosis of PC-3 and LNCaP cells treated with
drugs in vitro was measured by flow cytometry (Figure 2).
Compared with the control group, the apoptosis rates of
PC-3 and LNCaP cells treated with I131-PSCA-mAb,
PSCA-mAb or I131-IgG were gradually increased. The
apoptosis rates of PC-3 and LNCaP cells reached the
maximum of 50% and 46%, respectively, when cells were
treated with I131-PSCA-mAb.h and 24 h after intravenous injection of I131-PSCA-mAb.
cells; b: tumor-bearing nude mice inoculated with androgen-
Figure 5 The ratio of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in the tumor-bearing nude mice at 1 h, 4 h, 8 h,
12 h and 24 h after intravenous injection of I131-PSCA-mAb.
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The invasion ability of PC-3 and LNCaP cells treated with
drugs was determined by transwell culture (Figure 3).
Compared with the control group, there was no significant
difference in the invasion ability between the group
treated with PSCA-mAb and the group treated with I131-
IgG. When cells were treated with I131-PSCA-mAb, the
number of PC-3 and LNCaP cells that had invaded the
membrane was 36 and 34, respectively. The number of
invaded PC-3 and LNCaP cells treated with I131-PSCA-
mAb was significantly lower than that of the control
group (P < 0.01).
SPECT for tumor-bearing nude mice
The tumor-bearing nude mice inoculated with androgen-
independent PC-3 cells or androgen-dependent LNCaP
cells were examined by SPECT at 1 h, 4 h, 8 h, 12 h and
24 h after intravenous injection of I131-PSCA-mAbFigure 6 The tumor cell apoptosis of tumor-bearing nude mice treate
nude mice; b: androgen-dependent nude mice treated with I131-PSCA-mAb
independent nude mice treated with I131-PSCA-mAb).(Figure 4). The tumor developed clearly 1 h after intraven-
ous injection, and the kidney, stomach and intestine had
higher enhancement. The tumor enhancement region
gradually increased over time, while the abdomen, blood
and muscle enhancement decreased.
The variation of I131-PSCA-mAb in the tumor-bearing
nude mice over time was measured using the ROI
method (Figure 5). The variation of T/NT with time was
in accordance with the distribution in vivo. The T/NT of
androgen-independent and androgen-dependent tumor-
bearing nude mice increased with time and was highest
at 4.2 and 4.4 after 8 h. The T/NT stayed above 3.0 after
12 h, and the tumor could still be observed after 24 h.
Tumor cell apoptosis
The prostate tissue sections of the control and the ex-
perimental groups were analyzed by the TUNEL method
to detect tumor cell apoptosis. There were apoptoticd with I131-PSCA-mAb. (a: control group of androgen-dependent
; c: control group of androgen-independent nude mice; d: androgen-
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mice treated with I131-PSCA-mAb, and the number of
TUNEL-positive cells was obviously larger than that in
the control group (Figure 6).
Discussion
PSCA is an ideal candidate for the detection or immuno-
therapy of prostate cancer because it has increased expres-
sion specificity for prostate cancer and has a specific cell
surface location [12,20,21]. Radioimmunotherapy (RIT)
uses monoclonal antibodies against tumor-specific anti-
gens in conjunction with a particle-emitting radioisotope
to deliver cytocidal ionizing radiation directly to the tumor
[22]. In our study, the potential therapeutic efficacy of
anti-PSCA mAbs in conjunction with I131 for prostate
cancer was evaluated. We found that I131-PSCA-mAb
showed great advantages in radioimmunotherapy and
stronger positive anti-prostate tumor activity compared
with I131-IgG and PSCA-mAb. Therefore, I131-based elim-
ination of PSCA-producing cells seems to be a more effi-
cient therapeutic method.
The immunotherapeutic efficacy of PSCA-mAb has
been investigated by many studies considering PSCA as
a putative target in a prostate cancer model, and the re-
sults of these studies have indicated that anti-PSCA anti-
bodies have potential therapeutic roles for the treatment
of prostate cancer [21,23]. In our study, we found that
PSCA-mAb could inhibit the growth, apoptosis and mi-
gration of PC-3 and LNCaP cells to some extent. There-
fore, these results are consistent with previous reports
on anti-PSCA-based immunotherapy. RIT, which can
target the corresponding antigens via binding radionu-
clides to antibodies, has a promising role in the treat-
ment of metastatic melanoma, ovarian cancer and
metastatic colorectal cancer [24-26]. The characteristic
and complex interactions among the tumor, host,
antigen-antibody complex and radionuclide determine
the effectiveness of RIT [27]. In this study, the inhibitory
and apoptosis rates of PC-3 and LNCaP cells treated
with I131-PSCA-mAb reached up to the maximum of
84%, 80% and 50%, 46%, respectively, which were obvi-
ously higher than in the cells treated with I131-IgG or
PSCA-mAb. Therefore, I131-PSCA-mAb could effectively
inhibit the proliferation of cancer cells and promote the
apoptosis of cancer cells. Compared with the control
group, the number of invaded PC-3 and LNCaP cells
treated with I131-PSCA-mAb was significantly reduced,
which indicated that the invasion abilities of tumor cells
were significantly reduced by I131-PSCA-mAb.
Furthermore, the ratios of I131-PSCA-mAb in tumor to
intramuscular I131-PSCA-mAb (T/NT) in androgen-
independent and -dependent tumor-bearing nude mice
increased with time, which demonstrated that I131-PSCA-
mAb-targeted radioimmunotherapy may have few orminimal undesired toxic effects on the other tissues. The
T/NT stayed above 3.0 after 12 h, and the tumor could
still be observed after 24 h. Therefore, guided treatment
for prostate cancer could be precisely conducted. What is
more, the number of apoptotic cells in androgen-
independent or -dependent nude mice treated with I131-
PSCA-mAb was larger than that in the control group.
That is to say, I131-PSCA-mAb-targeted radioimmu-
notherapy could effectively promote cancer cell apoptosis
in tumor-bearing nude mice. However, PSCA-mAb might
not be able to specifically target non-PSCA-expressing
tumor cells. Therefore, the applicability of I131-PSCA-
mAb treatment in humans needs to be further explored.
Conclusion
In conclusion, I131-PSCA-mAb has the potential to be-
come a new targeted therapy drug for the radioimmu-
notherapeutic treatment of prostate cancer because it
exhibited good targeting ability and efficacy and few side
effects in nude mice models of human prostate cancer.
We optimistically anticipate that I131-PSCA-mAb can be
applied in clinical therapy.
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